Yahoo Web Search

Search results

1. • • Escherichia coli strains that produce the K1 polysaccharide capsule have long been associated with pathogenesis. This capsule is believed to increase the cell's invasiveness, allowing the bacteria to avoid phagocytosis and inactivation by complement.
     journals.asm.org › doi › full

     Escherichia coli K1's Capsule Is a Barrier to Bacteriophage T7

2. People also ask

   How many capsular chemotypes does E coli produce?

   • Although E. coli can produce around 80 distinct capsular chemotypes that are organised into four major groups 19, only a subset of these chemically distinct capsular types are associated with the capacity to cause invasive extraintestinal diseases; such infections include bloodstream infections (BSI), pyelonephritis and meningitis 20.

   Evolutionary and functional history of the Escherichia coli K1 capsule

   www.nature.com/articles/s41467-023-39052-w

   See all results for this question

   Is a K1 capsule good for Escherichia coli?

   • Escherichia coli is a leading cause of invasive bacterial infections in humans. Capsule polysaccharide has an important role in bacterial pathogenesis, and the K1 capsule has been firmly established as one of the most potent capsule types in E. coli through its association with severe infections.

   Evolutionary and functional history of the Escherichia coli K1 capsule

   www.nature.com/articles/s41467-023-39052-w

   See all results for this question

   Are E coli capsules functionally present in different phylogroups?

   • Our combined population genomic analysis coupled with in vitro experiments revealed that the capsule was functionally present in four distinct E. coli phylogroups providing immune protection irrespective of the genomic background.

   Evolutionary and functional history of the Escherichia coli K1 capsule

   www.nature.com/articles/s41467-023-39052-w

   See all results for this question

   Is Escherichia coli a phylogroup?

   • Enteropathogenic Escherichia coli (EPEC) was also found in 23% of CRC strains and 7.1% of control strains ( p < 0.05). Phylogroup A was predominant in control group specimens, while E. coli isolates from CRC patients belonged most frequently to phylogroups D and B2.

   Mucosa-Associated Escherichia coli in Colorectal Cancer Patients and

   www.ncbi.nlm.nih.gov/pmc/articles/PMC8594973/

   See all results for this question

   Is capsule polysaccharide a bacterial decoy for antimicrobial peptides?

   • Llobet, E., Tomás, J. M. & Bengoechea, J. A. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 154, 3877–3886 (2008). Whitfield, C. & Roberts, I. S. Structure, assembly and regulation of expression of capsules in Escherichia coli. Mol. Microbiol. 31, 1307–1319 (1999).

   Evolutionary and functional history of the Escherichia coli K1 capsule

   www.nature.com/articles/s41467-023-39052-w

   See all results for this question

3. www.ncbi.nlm.nih.gov › pmc › articlesMucosa-Associated Escherichia coli in Colorectal Cancer Patients...

   www.ncbi.nlm.nih.gov › pmc › articles

   Nov 9, 2021 · Accumulating evidence indicates that specific strains of mucosa-associated Escherichia coli ( E. coli) can influence the development of colorectal carcinoma. This study aimed to investigate the prevalence and characterization of mucosa-associated E. coli obtained from the colorectal cancer (CRC) patients and control group.

4. www.ncbi.nlm.nih.gov › pmc › articlesEnteropathogenic Escherichia coli Infection in Cancer and ...

   www.ncbi.nlm.nih.gov › pmc › articles

   May 5, 2021 · The role of enteropathogenic Escherichia coli (EPEC) as a cause of diarrhea in cancer and immunocompromised patients is controversial. Quantitation of fecal bacterial loads has been proposed as a method to differentiate colonized from truly infected patients.

   • Author: Adilene Olvera, Hannah Carter, Anubama Rajan, Lily G. Carlin, Xiaomin Yu, Xi Lei Zeng, Samuel Shelbu...
   • DOI: 10.1093/cid/ciaa1394

   • Publish Year: 2021
   • Published: 2021/05/05

5. Videos

   • 

     2:13

     youtube.com

     E. coli

     Jan 26, 2018

     206K Views

   • 

     1:25

     youtube.com

     The dangers of E. coli

     Jun 24, 2015

     234.7K Views

   • 

     9:08

     youtube.com

     Escherichia coli

     Nov 17, 2018

     9.9K Views

   View all

6. www.nature.com › articles › s41467/023/39052-wEvolutionary and functional history of the Escherichia coli ...

   www.nature.com › articles › s41467/023/39052-w

   Jun 15, 2023 · Capsule polysaccharide has an important role in bacterial pathogenesis, and the K1 capsule has been firmly established as one of the most potent capsule types in E. coli through its association...

7. news.harvard.edu › gazette › storyStudy examines how colibactin causes cancer - Harvard Gazette

   news.harvard.edu › gazette › story

   • Cached

   Feb 19, 2019 · In an effort to understand how colibactin, a compound produced by certain strains of E. coli, may be connected to the development of colorectal cancer, Harvard researchers are exploring how the compound damages DNA to produce DNA adducts.

8. www.cancerbiomed.org › content › 19/2/147Tumorigenic bacteria in colorectal cancer: mechanisms and ...

   www.cancerbiomed.org › content › 19/2/147

   • Cached

   These bacteria can cause host DNA damage by genotoxic substances, including colibactin secreted by pks + Escherichia coli, B. fragilis toxin (BFT) produced by Bacteroides fragilis, and typhoid toxin (TT) from Salmonella.

9. www.nature.com › articles › s41467/021/21162-yGenomic aberrations after short-term exposure to colibactin ...

   www.nature.com › articles › s41467/021/21162-y

   Feb 12, 2021 · Genotoxic colibactin-producing pks + Escherichia coli induce DNA double-strand breaks, mutations, and promote tumor development in mouse models of colorectal cancer (CRC). Colibactin’s...

10. www.nature.com › articles › s41416/021/01273-5A bacterial mutational footprint in colorectal cancer genomes

    www.nature.com › articles › s41416/021/01273-5

    We recently demonstrated that pks+ Escherichia coli induce a specific mutational pattern using intestinal organoids and these mutations are present in the genomes of colorectal cancer.